BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://murmitoyen.com/events/vanille/udem/
X-WR-TIMEZONE:America/Montreal
BEGIN:VEVENT
UID:69e25c707cc6f
DTSTAMP:20260417T121440
DTSTART:20120420T110000
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20120420T123000
URL:https://murmitoyen.com/events/vanille/udem/detail/69858
LOCATION:Université de Montréal - Pavillon Roger-Gaudry\, 2900\, chemin d
 e la Tour\, Montréal\, QC\, Canada\, H3T 1J6
SUMMARY:Conférence du Dr. Vincent Mascitti (Pfizer)
DESCRIPTION:Titre : Discovery of Ertugliflozin: An anti-diabetic agent fro
 m the structurally unique dioxa-bicyclo[3.2.1]octane class of SGLT2 inhibi
 tors.La conférence sera prononcée par le Dr. Vincent Mascitti\, chimist
 e médicinal aux laboratoires Groton de Pfizer Global Research & Developm
 ent. Elle sera donnée en anglais.Résumé : Diabetes looms as a threat t
 o human health worldwide. As a result\, considerable research efforts are 
 devoted to identify new and efficacious anti-diabetic agents lacking the s
 ide effects associated with some of the current drugs (hypoglycemia\, weig
 ht gain). Inhibition of sodium-dependent glucose cotransporter 2 (SGLT2)\,
  a transporter located in the kidney\, is a mechanism that promotes glucos
 uria and therefore\, reduction of plasma glucose concentration. Since the 
 mechanism operates in a glucose-dependent and insulin-independent manner\,
  and is associated with weight loss\, it has emerged as a very promising a
 pproach to the pathophysiologic treatment of type 2 diabetes. In this pres
 entation\, we will describe the medicinal and synthetic organic chemistry 
 rationale that led to the rapid identification of Ertugliflozin (PF-049717
 29)\, an anti-diabetic agent currently in development and belonging to a n
 ew class of SGLT2 inhibitors bearing a dioxa-bicyclo[3.2.1]octane bridged 
 ketal motif.À propos du conférencier : Vincent Mascitti was born in Rei
 ms\, France and received his diploma in chemical engineering from the ECPM
  (Strasbourg\, France) in 1999. He completed his Ph.D. in 2003 with Profes
 sor Hanessian (University of Montreal\, Canada) on the total synthesis of 
 natural products bearing deoxypropionate motifs (e.g.\, doliculide and bor
 relidin)\, and the synthesis of bioactive oligosaccharides. He did his pos
 tdoctoral studies in the laboratories of Professor E. J. Corey where he co
 mpleted the first total synthesis of the ladderane-containing natural prod
 uct pentacycloanammoxic acid. Vincent joined Pfizer in 2006\, where as a m
 edicinal chemist in the CVMED chemistry department\, he contributed to var
 ious diabetes and obesity related projects. Particularly\, Vincent was the
  driving force behind the design and synthesis of SGLT2 inhibitor PF-04971
 729\, a clinical candidate currently in phase 2 and being evaluated for ty
 pe 2 diabetes treatment. Vincent is the (co)author of about 30 publication
 s and patent applications. He is currently a Senior Director at Pfizer and
  Synthesis Head in the CVMED medicinal chemistry department.Information su
 pplémentaire
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Montreal
X-LIC-LOCATION:America/Montreal
END:VTIMEZONE
END:VCALENDAR